Ocean Biomedical Changes Auditors
Ticker: OCEA · Form: 8-K · Filed: Dec 17, 2024 · CIK: 1869974
Sentiment: neutral
Topics: auditor-change, disclosure
Related Tickers: OCEA
TL;DR
OCEA swapped auditors, Citrin Cooperman out, no drama reported.
AI Summary
Ocean Biomedical, Inc. announced on December 17, 2024, a change in its certifying accountant. The company has dismissed its previous independent registered public accounting firm, Citrin Cooperman & Company, LLP, effective December 17, 2024. This change is not related to any disagreements or reportable events.
Why It Matters
A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting.
Risk Assessment
Risk Level: low — The filing is a standard disclosure of a change in independent auditors and does not indicate any financial distress or significant operational changes.
Key Players & Entities
- Ocean Biomedical, Inc. (company) — Registrant
- Citrin Cooperman & Company, LLP (company) — Dismissed Certifying Accountant
- December 17, 2024 (date) — Date of change in accountant
FAQ
Who was Ocean Biomedical, Inc.'s previous independent registered public accounting firm?
Ocean Biomedical, Inc.'s previous independent registered public accounting firm was Citrin Cooperman & Company, LLP.
When was the dismissal of Citrin Cooperman & Company, LLP effective?
The dismissal of Citrin Cooperman & Company, LLP was effective on December 17, 2024.
Did Ocean Biomedical, Inc. have any disagreements with Citrin Cooperman & Company, LLP?
No, the filing states that there were no disagreements or any other adverse matters that led to the dismissal of Citrin Cooperman & Company, LLP.
Has Ocean Biomedical, Inc. engaged a new independent registered public accounting firm?
The filing does not explicitly state that a new firm has been engaged, but it indicates the dismissal of the previous one.
What is the filing date of this 8-K report?
This 8-K report was filed on December 17, 2024.
Filing Stats: 452 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2024-12-17 16:30:34
Key Financial Figures
- $0.0001 — ction 12(b) of the Act: Common Stock, $0.0001 par value OCEA The Nasdaq Stock Mar
- $11.50 — of common stock at an exercise price of $11.50 OCEAW The Nasdaq Stock Market LLC
Filing Documents
- form8-k.htm (8-K) — 42KB
- 0001493152-24-050414.txt ( ) — 263KB
- ocea-20241217.xsd (EX-101.SCH) — 4KB
- ocea-20241217_def.xml (EX-101.DEF) — 29KB
- ocea-20241217_lab.xml (EX-101.LAB) — 36KB
- ocea-20241217_pre.xml (EX-101.PRE) — 27KB
- form8-k_htm.xml (XML) — 6KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 17, 2024 OCEAN BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-40793 87-1309280 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 55 Claverick St. , Room 325 Providence , RI 02903 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (401) 444-7375 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Common Stock, $0.0001 par value OCEA The Nasdaq Stock Market LLC Warrants, each warrant exercisable for one share of common stock at an exercise price of $11.50 OCEAW The Nasdaq Stock Market LLC (Title of Each Class) (Trading Symbol) (Name of Each Exchange on Which Registered) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (CFR 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (CFR 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 4.01. Changes in Registrant's Certifying Accountants Appointment of New Independent Registered Public Accounting Firm On December 17, 2024, the Audit Committee approved the engagement of Berkowitz Pollack Brant ("BPB") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. During the Company's two most recent fiscal years ended December 31, 2023 and 2022, and during the interim period through December 17, 2024, neither the Company nor anyone acting on its behalf consulted with BPB regarding any of the matters described in Items 304(a)(2)(i) and (ii) of Regulation S-K. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 17, 2024 OCEAN BIOMEDICAL, INC. By: /s/ Jolie Kahn Jolie Kahn Chief Financial Officer